Ignite Creation Date:
2024-05-06 @ 8:14 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06307938
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-03-13
First Post:
2024-03-06
Brief Title:
Circulating Tumor DNA in Patients Summoned for Colonoscopy - a Liquid Biopsy for Detection Characterization Individualized Treatment and Follow-up of Colorectal Cancer
Sponsor:
Helse Nord-Trøndelag HF
Organization:
Helse Nord-Trøndelag HF
Study Overview
Official Title:
Circulating Tumor DNA in Patients Summoned for Colonoscopy - a Liquid Biopsy for Detection Characterization Individualized Treatment and Follow-up of Colorectal Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CoLiQ
Brief Summary:
CoLiQ is an observational study designed to evaluate the clinical usefulness of circulating tumor DNA ctDNA markers found in blood as a liquid biopsy for diagnosis prognosis and follow-up of colorectal cancer The main questions it aims to answer are 1 Can a panel of ctDNA markers identify CRC patients among the other patients summoned for colonoscopy and 2 Does the type number and level of ctDNA markers vary with the subtype and clinical course of CRC Participants will be asked to answer a questionnaire and give a blood sample at inclusion In addition patients with CRC will be asked to give an extra test tube at their routine treatment and follow-up blood sampling
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None